메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Brii Biosciences Presents Late-Breaking Data from Ongoing P…

Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-179 anti-HBs responders showing faster and greater HBsAg reduction DURHAM, N.C. and BEIJING, Nov. 10, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and cho
- 김갑성 기자
- 2025-11-10 21:30
Halia Therapeutics to Present Groundbreaking Data on Nove…

- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - LEHI, Utah, Nov. 10, 2025 -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the
- 김갑성 기자
- 2025-11-10 21:15
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibit…

70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare and intractable diseases, today shared the interim Phase II clinical data for its "first-in-class" Tosposertib (TU2218), a dual inhibitor against TGFβ type I receptor (TGFβRI /ALK5) and VEGFR2. The study eva
- 김갑성 기자
- 2025-11-10 21:00
Fapon to Showcase Innovative Molecular Diagnostic Solutio…

BOSTON, Nov. 10, 2025 -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-Generation Sequencing (NGS) library preparation. By integrating AI-driven design and high-throughput assays, Fapon actively leverages its AI-enabled enzyme engineering platform to improve product performance. Its showcased enzymes and reagents are engineered to enhance the accuracy, efficiency, and rel
- 김갑성 기자
- 2025-11-10 20:30
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II C…

NANJING, China, Nov. 10, 2025 -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People's Hospital. This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moder
- 김갑성 기자
- 2025-11-10 20:06
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in…

SEOUL, South Korea, Nov. 10, 2025 -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Cholangitis (PSC), a rare and progressive liver disease with no approved treatments on November 5 (local time in the U.S.). LB-P8: A First in Class Candidate Targeting the Gut-Liver axis PSC is a cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of the bile d
- 김갑성 기자
- 2025-11-10 20:00
Akeso Announces First Patient Dosed in Phase I Trial of Pers…

HONG KONG, Nov. 10, 2025 -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company's first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), for the adjuvant treatment of pancreatic cancer following surgical resection. AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakth
- 김갑성 기자
- 2025-11-10 19:39
MediTrust Health and Sino Biopharm Sign Strategic Cooperat…

HONG KONG, Nov. 10, 2025 -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("MediTrust Health") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage. Mr. Tse Hsin, Executive Director an
- 김갑성 기자
- 2025-11-10 14:18
Jiahui International Cancer Center Attracts Global Patients with…

SHANGHAI, Nov. 10, 2025 -- On November 7, Jiahui International Cancer Center (JICC) successfully treated a 78-year-old patient from New Zealand with relapsed multiple myeloma using CAR-T therapy, highlighting JICC's growing reputation as a destination for cutting-edge oncology care for international patients. The patient received Zevor-cel (Zevor-cel Injection) CAR-T therapy and was discharged in stable condition. The patient, a retired family medicine doctor with 40 years of experience, had exhausted all conventional treatment options in his home country. Following a recommendation fr
- 김갑성 기자
- 2025-11-10 14:09
Rona Therapeutics Presents Phase 1 Data for RN0361, a Lon…

NEW ORLEANS, Nov. 10, 2025 -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycerides (TG) lasting at least six months in a single dose first-in-human trial, establishing a potential best-in-class profile to prevent pancreatitis in severe hypertriglyceridemia (HTG) and reduce cardiovascular risk (CVD) from atherogenic lipoproteins. The data were presented today at the American Heart Associatio
- 김갑성 기자
- 2025-11-10 12:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 21시 20분